XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 11 - Significant Transactions - Allocation of Preliminary Price (Details) - USD ($)
$ in Thousands
Oct. 20, 2021
Dec. 31, 2021
Mar. 31, 2021
Goodwill, Ending Balance   $ 293,542 $ 160,841
Agena [Member]      
Cash and cash equivalents $ 7,544    
Accounts receivable (a) [1] 11,100    
Other current assets (b) [2] 24,324    
Total current assets 42,968    
Property, plant and equipment/ noncurrent assets 16,976    
Deferred tax asset 792    
Goodwill, Ending Balance [3] 136,006    
Total assets acquired 365,942    
Accounts payable 2,174    
Unearned revenues 2,713    
Other current liabilities 12,549    
Total current liabilities 17,436    
Deferred tax liability 31,907    
Other noncurrent liabilities 8,262    
Total liabilities assumed 57,605    
Total purchase price, net of cash acquired $ 300,793    
Agena [Member] | Customer Relationships [Member]      
Intangible assets, life (Year) 16 years    
Intangible assets [4] $ 107,100    
Agena [Member] | Intellectual Property [Member]      
Intangible assets, life (Year) 10 years    
Intangible assets [4] $ 46,200    
Agena [Member] | Trade Names [Member]      
Intangible assets [4] $ 15,900    
[1] Trade receivables, net, which is expected to be collected.
[2] Includes $6,062 of inventory step-up, which was amortized entirely within the third quarter of fiscal year 2022.
[3] Acquired goodwill of $136,006, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from the value of expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.
[4] Customer relationships and intellectual property are currently expected to be amortized on a straight line basis over a weighted average 14.2 year period. The identified intangible assets will be amortized on a straight line basis over their useful lives, which approximates the pattern that the assets' economic benefits are expected to be consumed over time. Tradenames are considered indefinite-lived intangibles. Amortization expense for customer relationships will be amortized to general and administrative expenses; amortization expense for intellectual property will be recorded to cost of revenues. During the period from October 20, 2021 until December 31, 2021, $1,320 of amortization expense was recorded to general and administrative costs and $911 of amortization expense was recorded to cost of revenues and allocated to the Clinical Genomics Division. Once our final valuation is complete, the amount of amortization expense will be trued up and amortization will be based on our final allocation.